BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Ventyx Biosciences, Inc. (NASDAQ:VTYX) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/vtyx.
What is this all about?
The lawsuit alleges that the Offering Documents for Ventyx Biosciences' IPO were negligently prepared, and that Defendants made materially false and/or misleading statements regarding the Company's business, operations, and prospects. Specifically, that: (1) Ventyx's lead clinical product candidate VTX958 was less effective in treating psoriasis than Defendants had led investors to believe; (2) as a result, VTX958's clinical and/or commercial prospects were overstated; ...